Email this article Significance of regular somatostatin analogues and interferon-alfa application in patients with highly differentiated neuroendocrine tumors (clinical case)
- Authors: Emelianov G.S.1, Gorbunova V.A1, Orel N.F1, Markovich A.A1, Kuzmiovn A.E1, Selchuk V.Y.1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center
- Issue: Vol 19, No 6 (2014)
- Pages: 30-32
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/40104
- DOI: https://doi.org/10.17816/onco40104
- ID: 40104
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Galina S. Emelianov
N.N. Blokhin Russian Cancer Research Center
Email: docgalina@mail.ru
MD 115478, Moscow, Russian Federation
V. A Gorbunova
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
N. F Orel
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
A. A Markovich
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
A. E Kuzmiovn
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
V. Yu Selchuk
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
References
- Kaltsas G., Besser G., Grossman A. The Diagnosis and medical management of advanced neuroendocrine tumors. Endocrine Rev. 2004; 25(3): 458-511.
- Funa К., Alm G.V., Ronnblom L., Oberg K. Evaluation of the natural killer cell-interferon system in patients with mid-gut carcinoid tumours treated with leucocyte interferon. Clin. Exp. Immunol. 1983; 53(3): 716-24.
- Rosewicz, S. Detjen K., Scholz A., Marschall Z. Interferon-alpha: regulatory effects on cell cycle and angiogenesis. Neuroendocrinology. 2004; 80(1): 85-93.
- Aparicio-Pages M.N., Verspaget H.W., Pena A.S., Jansen J.B., Lamers C.B. Natural killer cell activity in patients with neuroendocrine tumours of the gastrointestinal tract; relation with circulating gastrointestinal hormones. J. Neuropeptid. 1991; 20(1): 1-7.
- Oberg K. Interferon in the management of neuroendocrine GEP tumors. Digest. 2000; 62 (Suppl. 1): 92-7.
- Eriksson В., Oberg K. Interferon therapy of malignant endocrine pancreatic tumors. In: Endocrine Tumors of the Pancreas: Recent Advanced in Research and Management. 1995: 451-60.
- Reisine T., Bell G. Molecular biology of somatostatin receptors. Endocr. Rev. 1995; 16: 427-42.
- Susini C., Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann. Oncol. 2006; 17(12): 1733-42.
- Kolby L., Persson G., Franzen S., Ahren B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br. J. Surg. 2003; 90(6): 687-93.
- Faiss S., Pape U.F., Bohmig M., Dorffel Y., Mansmann U., Golder W. et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. J. Clin. Oncol. 2003; 21: 2689-96.
- Arnold R., Rinke A., Klose K., Muller H., Wied M., Zamzow K. et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: A randomized trial. Clin. Gastroenterol. Hepatol. 2005; 3: 761-71.
